In‑hospital and long‑term outcomes of congestive heart failure: Predictive value of B‑type and amino‑terminal pro‑B‑type natriuretic peptides and their ratio

Dai,Yuxiang; Yang,Jun; Takagi,Atsutoshi; Konishi,Hakuoh; Miyazaki,Tetsuro; Masuda,Hiroshi; Shimada,Kazunori; Miyauchi,Katsumi; Daida,Hiroyuki

doi:10.3892/etm.2017.4686

In‑hospital and long‑term outcomes of congestive heart failure: Predictive value of B‑type and amino‑terminal pro‑B‑type natriuretic peptides and their ratio

Authors:
- Yuxiang Dai
- Jun Yang
- Atsutoshi Takagi
- Hakuoh Konishi
- Tetsuro Miyazaki
- Hiroshi Masuda
- Kazunori Shimada
- Katsumi Miyauchi
- Hiroyuki Daida
View Affiliations

Affiliations: Department of Cardiology, Juntendo University Hospital, Tokyo 113‑8421, Japan, Department of Cardiovascular Medicine, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277100, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/etm.2017.4686
Pages: 1715-1721

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Relative changes in B‑type natriuretic peptide (BNP) and amino terminal pro‑BNP (NT‑proBNP) levels may help to assess the risk of congestive heart failure (CHF). However, whether these levels at the time of admission enable the prediction of outcomes with acute exacerbation remains unknown. The current study determined the abilities of BNP, NT‑proBNP and their ratio to predict in‑hospital and long‑term outcomes of patients with CHF. Patients who were admitted to the cardiac care unit of Juntendo University Hospital (Tokyo, Japan) with acute CHF onset were consecutively enrolled into the present observational study. Serum levels of BNP and NT‑proBNP were immediately measured on admission, and other biomarkers and clinical data were also investigated. Of 195 enrolled patients, 16 (8.2%) succumbed to CHF in hospital and 124 (69.3%) reached the endpoint of mortality or readmission following a median follow‑up of 14 months. Multiple linear regression analysis revealed body mass index, low density lipoprotein cholesterol, hemoglobin, estimated glomerular filtration rate and C‑reactive protein as independent predictors of the NT‑proBNP/BNP ratio. BNP, NT‑proBNP and their ratio were significantly higher among those who succumbed to CHF than in those who remained alive in hospital (P<0.05). Logistic regression analysis indicated that the ratio was an independent predictor for in‑hospital mortality and long‑term outcomes. In conclusion, the ratio of NT‑proBNP to BNP more effectively predicts in‑hospital outcomes than either factor alone and it may also help to predict outcomes among patients with acute exacerbation of HF.

View Figures

View References

1	Bozkurt B and Mann DL: Use of biomarkers in the management of heart failure: Are we there yet? Circulation. 107:1231–1233. 2003. View Article : Google Scholar : PubMed/NCBI
2	Jortani SA, Prabhu SD and Valdes R Jr: Strategies for developing biomarkers of heart failure. Clin Chem. 50:265–278. 2004. View Article : Google Scholar : PubMed/NCBI
3	Harrison A and Amundson S: Evaluation and management of the acutely dyspneic patient: The role of biomarkers. Am J Emerg Med. 23:371–378. 2005. View Article : Google Scholar : PubMed/NCBI
4	Costello-Boerrigter LC and Burnett JC Jr: The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med. 2:194–201. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jarolim P: Serum biomarkers for heart failure. Cardiovasc Pathol. 15:144–149. 2006. View Article : Google Scholar : PubMed/NCBI
6	Aviles JM and Aviles RJ: Advances in cardiac biomarkers. Emerg Med Clin North Am. 23:959–975. 2005. View Article : Google Scholar : PubMed/NCBI
7	Moe GW: BNP in the diagnosis and risk stratification of heart failure. Heart Fail Monit. 4:116–122. 2005.PubMed/NCBI
8	Bettencourt P: NT-proBNP and BNP: Biomarkers for heart failure management. Eur J Heart Fail. 6:359–363. 2004. View Article : Google Scholar : PubMed/NCBI
9	Richards M and Troughton RW: NT-proBNP in heart failure: Therapy decisions and monitoring. Eur J Heart Fail. 6:351–354. 2004. View Article : Google Scholar : PubMed/NCBI
10	Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie WS, Duffy V and Cawley P: The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 56:327–333. 2006.PubMed/NCBI
11	Moe GW: B-type natriuretic peptide in heart failure. Curr Opin Cardiol. 21:208–214. 2006.PubMed/NCBI
12	Palazzuoli A, Gallotta M, Quatrini I and Nuti R: Natriuretic peptides (BNP and NT-proBNP): Measurement and relevance in heart failure. Vasc Health Risk Manag. 6:411–418. 2010. View Article : Google Scholar : PubMed/NCBI
13	McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM and Burnett JC Jr: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 47:874–880. 2006. View Article : Google Scholar : PubMed/NCBI
14	Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, et al: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:161–167. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hayek S and Nemer M: Cardiac natriuretic peptides: From basic discovery to clinical practice. Cardiovasc Ther. 29:362–376. 2011. View Article : Google Scholar : PubMed/NCBI
16	Valle R and Aspromonte N: Use of brain natriuretic peptide and bioimpedance to guide therapy in heart failure patients. Contrib Nephrol. 164:209–216. 2010. View Article : Google Scholar : PubMed/NCBI
17	van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW and Pinto YM: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 53:884–890. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tagore R, Ling LH, Yang H, Daw HY, Chan YH and Sethi SK: Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol. 3:1644–1651. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bednarek-Skublewska A, Zaluska W and Ksiazek A: The relationship between serum level of N-terminal pro-B-type natriuretic peptide and nutritional status, and inflammation in chronic hemodialysis patients. Clin Nephrol. 73:14–20. 2010. View Article : Google Scholar : PubMed/NCBI
20	Nishiyama K, Tsutamoto T, Tanaka T, Fujii M, Yamamoto T, Yamaji M and Horie M: Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion. Int Heart J. 50:183–190. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA and Hammarsten O: Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol. 99:445–452. 2010. View Article : Google Scholar : PubMed/NCBI
22	De Bold AJ: Atrial natriuretic factor: A hormone produced by the heart. Science. 230:767–770. 1985. View Article : Google Scholar : PubMed/NCBI
23	Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, Sabatino L, Forini F, Manfredi C and Donato L: Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 21:170–179. 1998. View Article : Google Scholar : PubMed/NCBI
24	Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F and Van Veldhuisen DJ: Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: Determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace. 8:482–487. 2006. View Article : Google Scholar : PubMed/NCBI
25	Falcão LM, Pinto F, Ravara L and van Zwieten PA: BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J Renin Angiotensin Aldosterone Syst. 5:121–129. 2004. View Article : Google Scholar : PubMed/NCBI
26	Vanderheyden M, Bartunek J, Filippatos G, Goethals M, Vlem BV and Maisel A: Cardiovascular disease in patients with chronic renal impairment: Role of natriuretic peptides. Congest Heart Fail. 14 4 Suppl 1:1–42. 2008. View Article : Google Scholar
27	Bayes-Genis A, DeFilippi C and Januzzi JL Jr: Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol. 101:89–94. 2008. View Article : Google Scholar : PubMed/NCBI
28	Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y and Yoshimasa Y: Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: The Suita Study. Endocr J. 57:727–733. 2010. View Article : Google Scholar : PubMed/NCBI
29	Srisawasdi P, Vanavanan S, Charoenpanichkit C and Kroll MH: The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 133:14–23. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kälsch H, Neumann T and Erbel R: Less increase of BNP and NT-proBNP levels in obese patient with decompensated heart failure: Interpretation of natriuretic peptides in obesity. Int J Cardiol. 133:e22–e24. 2009. View Article : Google Scholar : PubMed/NCBI
31	deFilippi CR, Seliger SL, Maynard S and Christenson RH: Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem. 53:1511–1519. 2007. View Article : Google Scholar : PubMed/NCBI
32	DeFilippi C, van Kimmenade RR and Pinto YM: Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol. 101:82–88. 2008. View Article : Google Scholar : PubMed/NCBI
33	McCullough PA and Sandberg KR: B-type natriuretic peptide and renal disease. Heart Fail Rev. 8:355–358. 2003. View Article : Google Scholar : PubMed/NCBI